Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants

@article{Khoo2015NetworkMA,
  title={Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants},
  author={Ai Leng Khoo and Hui Jun Zhou and Monica Teng and Liang Lin and Ying Jiao Zhao and Lay Beng Soh and Yee Ming Mok and Boon Peng Lim and Kok Peng Gwee},
  journal={CNS Drugs},
  year={2015},
  volume={29},
  pages={695-712}
}
BackgroundMajor depressive disorder (MDD) impacts health, quality of life and workplace productivity. Antidepressant treatment is the primary therapeutic intervention. This study assessed the efficacy and tolerability of new generation antidepressants and their cost-effectiveness in the Singapore healthcare system.MethodsWe conducted a systematic search for head-to-head randomised controlled trials on ten antidepressants (agomelatine, duloxetine, escitalopram, fluvoxamine, fluoxetine… 
Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews
TLDR
Evidence is compiled from multiple meta-analyses based on systematic reviews and provides a clearer picture for assessing the efficacy and tolerability of SSRIs to clarify current gaps and direction of future research in this category of antidepressants.
Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
TLDR
Since the individual history of each patient is important for the prognosis of depression, DES and ISM simulation methods may be more appropriate than the others for a pragmatic representation of the course of depression.
Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression
TLDR
The results showed that the number of study sites (single or multi-center) and the type of setting (inpatient or noninpatient) are important factors affecting the efficacy of antidepressants.
Considering the societal perspective in economic evaluations: a systematic review in the case of depression
TLDR
The results show that societal costs might alter the conclusions in cost-utility analyses, demonstrating that the results of economic evaluations can be affected by different methods available for estimating non-healthcare costs.
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
TLDR
This study found that, from a cost-effectiveness point of view, ECT should be the first-hand option for individuals with TRD, when other first line treatments have failed.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
TLDR
First-line psychological treatment recommendations for acute MDD include cognitive-behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation (BA), and combined treatment with antidepressant treatment is recommended where feasible.
Effectiveness and side-effect profile of Vilazodone and Escitalopram in major Depressive Disorder – An observational study
TLDR
Vilazodone was found to be equally effective as escitalopram in patients with MDD and has the advantage of better tolerability as compared to escitalipram.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  • S. Kennedy, R. Lam, +15 authors R. Uher
  • Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2016
TLDR
Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice
TLDR
Agomelatine effectively reduced depressive symptoms (CGI-response and remission) with good general tolerability in a large number of non-selected German outpatients with major depressive disorder.
The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
TLDR
The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model
TLDR
Of the investigated antidepressants, escitalopram has the highest probability of remission and is the most effective and cost-effective pharmacological treatment in a primary care setting, when evaluated over a one year time-horizon.
Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
TLDR
EscITALopram was estimated as more effective and cost saving than generic venlafaxine XR in first-line MDD treatment in Sweden, driven by the effectiveness and tolerability advantages of escitalopram.
Antidepressant drug effects and depression severity: a patient-level meta-analysis.
TLDR
The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms.
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
TLDR
Clinically important differences exist between commonly prescribed antidepressants for both efficacy and acceptability in favour of escitalopram and sertraline, which might be the best choice when starting treatment for moderate to severe major depression in adults.
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants.
TLDR
The overall benefits of continuation- and maintenance-phase treatment of major depression with second-generation antidepressants are demonstrated and the need for additional studies of comparative differences among drugs is emphasized.
Treating Depression After Initial Treatment Failure: Directly Comparing Switch and Augmenting Strategies in STAR*D
TLDR
Findings tentatively suggest that those who complete an initial treatment of 12 weeks or more and have a partial response with residual mild depressive severity may benefit more from augmentation relative to switching.
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
TLDR
Although the magnitude of global changes in depression, anxiety, and quality of life was larger with sertraline than fluoxetine, none of the between-group differences reached statistical significance, and sERTraline was associated with significantly superior performance on the Leeds Sleep Evaluation scale and on SIP items relating to sleep and rest, emotional behaviour and ambulation.
The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression
TLDR
It is concluded that remission has a substantial health economic impact on patients treated for depression, which further strengthens the importance of aiming for full remission in the treatment of depression.
Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients
TLDR
Mirtazapine is as effective and well tolerated as fluoxetine in the treatment of patients with severe depression and produces significantly better improvements on ‘sleeping assessment 1’ and “much/very much improved” patients tended to be greater with mirtazAPine.
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
TLDR
In this study, agomelatine showed superior antidepressant efficacy over fluoxetine in treating patients with a severe episode of major depressive disorder after 8 weeks of treatment with a good tolerability profile.
...
1
2
3
4
5
...